{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:41:32Z","timestamp":1793814092056,"version":"4.6.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fujian Provincial Science and Technology Plan Project","award":["2023Y41010075"],"award-info":[{"award-number":["2023Y41010075"]}]},{"name":"Fujian Provincial Science and Technology Plan Project","award":["2023Y41010075"],"award-info":[{"award-number":["2023Y41010075"]}]},{"name":"the Natural Science Foundation of Fujian Province","award":["2021J011304"],"award-info":[{"award-number":["2021J011304"]}]},{"name":"the Natural Science Foundation of Fujian Province","award":["2021J011304"],"award-info":[{"award-number":["2021J011304"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-72864-4","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T14:03:42Z","timestamp":1727445822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical characteristics and influencing factors of anti-PD-1\/PD-L1-related severe cardiac adverse event: based on FAERS and TCGA databases"],"prefix":"10.1038","volume":"14","author":[{"given":"Xitong","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jierong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bitao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maobai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"72864_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi, A. et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell. Commun. Signal.20, 44. https:\/\/doi.org\/10.1186\/s12964-022-00854-y (2022).","journal-title":"Cell. Commun. Signal."},{"key":"72864_CR2","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069\u20131086. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0367 (2018).","journal-title":"Cancer Discov"},{"key":"72864_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel, J. A., Otsuka, A. & Kabashima, K. Anti-PD-1 and Anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations. Front. Oncol.8, 86. https:\/\/doi.org\/10.3389\/fonc.2018.00086 (2018).","journal-title":"Front. Oncol."},{"key":"72864_CR4","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley, R. K. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 401, 1853\u20131865. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4 (2023).","journal-title":"Lancet"},{"key":"72864_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet. 398, 27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2 (2021).","journal-title":"Lancet"},{"key":"72864_CR6","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andre","year":"2020","unstructured":"Andre, T. et al. Pembrolizumab in microsatellite-instability-high Advanced Colorectal Cancer. N Engl. J. Med.383, 2207\u20132218. https:\/\/doi.org\/10.1056\/NEJMoa2017699 (2020).","journal-title":"N Engl. J. Med."},{"key":"72864_CR7","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/jamaoncol.2022.3707","volume":"8","author":"HH Yoon","year":"2022","unstructured":"Yoon, H. H. et al. Association of PD-L1 expression and other variables with Benefit from Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic review and Meta-analysis of 17 phase 3 Randomized clinical trials. JAMA Oncol.8, 1456\u20131465. https:\/\/doi.org\/10.1001\/jamaoncol.2022.3707 (2022).","journal-title":"JAMA Oncol."},{"key":"72864_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13045-022-01362-9","volume":"15","author":"Q Wu","year":"2022","unstructured":"Wu, Q., Qian, W., Sun, X. & Jiang, S. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J. Hematol. Oncol.15, 143. https:\/\/doi.org\/10.1186\/s13045-022-01362-9 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"72864_CR9","doi-asserted-by":"publisher","unstructured":"Wang, Y. et al. New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (review). Int. J. Oncol.63https:\/\/doi.org\/10.3892\/ijo.2023.5534 (2023).","DOI":"10.3892\/ijo.2023.5534"},{"key":"72864_CR10","doi-asserted-by":"publisher","unstructured":"Ramos-Casals, M. et al. Immune-related adverse events of checkpoint inhibitors. Nat. Rev. Dis. Primers. 6https:\/\/doi.org\/10.1038\/s41572-020-0160-6 (2020).","DOI":"10.1038\/s41572-020-0160-6"},{"key":"72864_CR11","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem, J. E. et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol.19, 1579\u20131589. https:\/\/doi.org\/10.1016\/S1470-2045(18)30608-9 (2018).","journal-title":"Lancet Oncol."},{"key":"72864_CR12","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood, S. S. et al. Myocarditis in patients treated with Immune Checkpoint inhibitors. J. Am. Coll. Cardiol.71, 1755\u20131764. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"72864_CR13","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi, J. J., Salem, J. E., Sosman, J. A., Lebrun-Vignes, B. & Johnson, D. B. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 391, 933. https:\/\/doi.org\/10.1016\/S0140-6736(18)30533-6 (2018).","journal-title":"Lancet"},{"key":"72864_CR14","doi-asserted-by":"publisher","first-page":"986357","DOI":"10.3389\/fphar.2022.986357","volume":"13","author":"F Wang","year":"2022","unstructured":"Wang, F., Wei, Q. & Wu, X. Cardiac arrhythmias associated with immune checkpoint inhibitors: a comprehensive disproportionality analysis of the FDA adverse event reporting system. Front. Pharmacol.13, 986357. https:\/\/doi.org\/10.3389\/fphar.2022.986357 (2022).","journal-title":"Front. Pharmacol."},{"key":"72864_CR15","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/jcpt.13707","volume":"47","author":"F Wang","year":"2022","unstructured":"Wang, F. & Wu, X. Cardiovascular toxicities associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system. J. Clin. Pharm. Ther.47, 1576\u20131584. https:\/\/doi.org\/10.1111\/jcpt.13707 (2022).","journal-title":"J. Clin. Pharm. Ther."},{"key":"72864_CR16","doi-asserted-by":"publisher","first-page":"616505","DOI":"10.3389\/fphar.2021.616505","volume":"12","author":"C Chen","year":"2021","unstructured":"Chen, C. et al. Cardiotoxicity Induced by Immune Checkpoint inhibitors: a Pharmacovigilance Study from 2014 to 2019 based on FAERS. Front. Pharmacol.12, 616505. https:\/\/doi.org\/10.3389\/fphar.2021.616505 (2021).","journal-title":"Front. Pharmacol."},{"key":"72864_CR17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA adverse event reporting system. Int. J. Med. Sci.10, 796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048 (2013).","journal-title":"Int. J. Med. Sci."},{"key":"72864_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown, E. G., Wood, L. & Wood, S. The medical dictionary for regulatory activities (MedDRA). Drug Saf.20, 109\u2013117. https:\/\/doi.org\/10.2165\/00002018-199920020-00002 (1999).","journal-title":"Drug Saf."},{"key":"72864_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","volume":"43","author":"O Caster","year":"2020","unstructured":"Caster, O., Aoki, Y., Gattepaille, L. M. & Grundmark, B. Disproportionality Analysis for Pharmacovigilance Signal Detection in small databases or subsets: recommendations for limiting false-positive associations. Drug Saf.43, 479\u2013487. https:\/\/doi.org\/10.1007\/s40264-020-00911-w (2020).","journal-title":"Drug Saf."},{"key":"72864_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate, A. & Evans, S. J. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf.18, 427\u2013436. https:\/\/doi.org\/10.1002\/pds.1742 (2009).","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"72864_CR21","doi-asserted-by":"publisher","unstructured":"Zhou, C. et al. Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. EClinicalMedicine59, 101967. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101967 (2023).","DOI":"10.1016\/j.eclinm.2023.101967"},{"key":"72864_CR22","doi-asserted-by":"publisher","unstructured":"Cirmi, S., El Abd, A., Letinier, L., Navarra, M. & Salvo, F. Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting System Database (FAERS). Cancers (Basel). 12https:\/\/doi.org\/10.3390\/cancers12040826 (2020).","DOI":"10.3390\/cancers12040826"},{"key":"72864_CR23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.mib.2017.11.001","volume":"39","author":"L Maier","year":"2017","unstructured":"Maier, L. & Typas, A. Systematically investigating the impact of medication on the gut microbiome. Curr. Opin. Microbiol.39, 128\u2013135. https:\/\/doi.org\/10.1016\/j.mib.2017.11.001 (2017).","journal-title":"Curr. Opin. Microbiol."},{"key":"72864_CR24","doi-asserted-by":"publisher","unstructured":"Jing, Y. et al. Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. J. Immunother Cancer. 10. https:\/\/doi.org\/10.1136\/jitc-2021-003779 (2022).","DOI":"10.1136\/jitc-2021-003779"},{"key":"72864_CR25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ccell.2019.01.011","volume":"35","author":"MD Hellmann","year":"2019","unstructured":"Hellmann, M. D. et al. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell.35, 329. https:\/\/doi.org\/10.1016\/j.ccell.2019.01.011 (2019).","journal-title":"Cancer Cell."},{"key":"72864_CR26","doi-asserted-by":"publisher","unstructured":"Thorsson, V. et al. The Immune Landscape of Cancer. Immunity48, 812\u2013830 e814. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.023 (2018).","DOI":"10.1016\/j.immuni.2018.03.023"},{"key":"72864_CR27","doi-asserted-by":"publisher","first-page":"A68","DOI":"10.5114\/wo.2014.47136","volume":"19","author":"K Tomczak","year":"2015","unstructured":"Tomczak, K., Czerwinska, P. & Wiznerowicz, M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp. Oncol. (Pozn). 19, A68\u201377. https:\/\/doi.org\/10.5114\/wo.2014.47136 (2015).","journal-title":"Contemp. Oncol. (Pozn)"},{"key":"72864_CR28","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1001\/jamaoncol.2019.2311","volume":"5","author":"JS Lee","year":"2019","unstructured":"Lee, J. S. & Ruppin, E. Multiomics Prediction of Response Rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 Ligand 1. JAMA Oncol.5, 1614\u20131618. https:\/\/doi.org\/10.1001\/jamaoncol.2019.2311 (2019).","journal-title":"JAMA Oncol."},{"key":"72864_CR29","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.1038\/s41467-020-18742-9","volume":"11","author":"Y Jing","year":"2020","unstructured":"Jing, Y. et al. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat. Commun.11, 4946. https:\/\/doi.org\/10.1038\/s41467-020-18742-9 (2020).","journal-title":"Nat. Commun."},{"key":"72864_CR30","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 16, 284\u2013287. https:\/\/doi.org\/10.1089\/omi.2011.0118 (2012).","journal-title":"OMICS"},{"key":"72864_CR31","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm, E. et al. The strengthening the reporting of Observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 370, 1453\u20131457. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X (2007).","journal-title":"Lancet"},{"key":"72864_CR32","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","volume":"4","author":"Y Oshima","year":"2018","unstructured":"Oshima, Y., Tanimoto, T., Yuji, K. & Tojo, A. EGFR-TKI-Associated interstitial pneumonitis in Nivolumab-treated patients with Non-small Cell Lung Cancer. JAMA Oncol.4, 1112\u20131115. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4526 (2018).","journal-title":"JAMA Oncol."},{"key":"72864_CR33","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","volume":"8","author":"S Shyam Sunder","year":"2023","unstructured":"Shyam Sunder, S., Sharma, U. C. & Pokharel, S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal. Transduct. Target. Ther.8, 262. https:\/\/doi.org\/10.1038\/s41392-023-01469-6 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"72864_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40801-021-00278-z","volume":"9","author":"MA Barbieri","year":"2022","unstructured":"Barbieri, M. A. et al. Adverse drug reactions with HER2-Positive breast Cancer Treatment: an analysis from the Italian Pharmacovigilance database. Drugs Real. World Outcomes. 9, 91\u2013107. https:\/\/doi.org\/10.1007\/s40801-021-00278-z (2022).","journal-title":"Drugs Real. World Outcomes"},{"key":"72864_CR35","doi-asserted-by":"publisher","first-page":"1005626","DOI":"10.3389\/fonc.2022.1005626","volume":"12","author":"MA Barbieri","year":"2022","unstructured":"Barbieri, M. A. et al. Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: an analysis from the Italian pharmacovigilance database. Front. Oncol.12, 1005626. https:\/\/doi.org\/10.3389\/fonc.2022.1005626 (2022).","journal-title":"Front. Oncol."},{"key":"72864_CR36","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","volume":"6","author":"LH Lehmann","year":"2021","unstructured":"Lehmann, L. H. et al. Clinical strategy for the diagnosis and treatment of Immune Checkpoint inhibitor-Associated myocarditis: a narrative review. JAMA Cardiol.6, 1329\u20131337. https:\/\/doi.org\/10.1001\/jamacardio.2021.2241 (2021).","journal-title":"JAMA Cardiol."},{"key":"72864_CR37","doi-asserted-by":"publisher","unstructured":"Samani, A. et al. Impact of age on the toxicity of immune checkpoint inhibition. J. Immunother Cancer. 8. https:\/\/doi.org\/10.1136\/jitc-2020-000871 (2020).","DOI":"10.1136\/jitc-2020-000871"},{"key":"72864_CR38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejca.2020.01.013","volume":"129","author":"C Baldini","year":"2020","unstructured":"Baldini, C. et al. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies. Eur. J. Cancer. 129, 71\u201379. https:\/\/doi.org\/10.1016\/j.ejca.2020.01.013 (2020).","journal-title":"Eur. J. Cancer"},{"key":"72864_CR39","doi-asserted-by":"publisher","first-page":"619385","DOI":"10.3389\/fonc.2021.619385","volume":"11","author":"X Huang","year":"2021","unstructured":"Huang, X. et al. Age-Associated changes in adverse events arising from Anti-PD-(L)1 therapy. Front. Oncol.11, 619385. https:\/\/doi.org\/10.3389\/fonc.2021.619385 (2021).","journal-title":"Front. Oncol."},{"key":"72864_CR40","doi-asserted-by":"publisher","first-page":"786046","DOI":"10.3389\/fimmu.2021.786046","volume":"12","author":"SK Wong","year":"2021","unstructured":"Wong, S. K., Nebhan, C. A. & Johnson, D. B. Impact of patient age on clinical efficacy and toxicity of checkpoint inhibitor therapy. Front. Immunol.12, 786046. https:\/\/doi.org\/10.3389\/fimmu.2021.786046 (2021).","journal-title":"Front. Immunol."},{"key":"72864_CR41","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1634\/theoncologist.2016-0450","volume":"22","author":"AS Betof","year":"2017","unstructured":"Betof, A. S. et al. Impact of age on outcomes with immunotherapy for patients with Melanoma. Oncologist. 22, 963\u2013971. https:\/\/doi.org\/10.1634\/theoncologist.2016-0450 (2017).","journal-title":"Oncologist"},{"key":"72864_CR42","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fimmu.2018.00315","volume":"9","author":"R Hid Cadena","year":"2018","unstructured":"Hid Cadena, R. et al. Checks and balances in Autoimmune Vasculitis. Front. Immunol.9, 315. https:\/\/doi.org\/10.3389\/fimmu.2018.00315 (2018).","journal-title":"Front. Immunol."},{"key":"72864_CR43","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12967-018-1467-x","volume":"16","author":"S Valpione","year":"2018","unstructured":"Valpione, S. et al. Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. J. Transl Med.16, 94. https:\/\/doi.org\/10.1186\/s12967-018-1467-x (2018).","journal-title":"J. Transl Med."},{"key":"72864_CR44","doi-asserted-by":"publisher","unstructured":"Delaunay, M. et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur. Respir J.50https:\/\/doi.org\/10.1183\/13993003.00050-2017 (2017).","DOI":"10.1183\/13993003.00050-2017"},{"key":"72864_CR45","doi-asserted-by":"publisher","first-page":"102590","DOI":"10.1016\/j.autrev.2020.102590","volume":"19","author":"P Triggianese","year":"2020","unstructured":"Triggianese, P. et al. Immune checkpoint inhibitors-induced autoimmunity: The impact of gender. Autoimmun. Rev.19, 102590. https:\/\/doi.org\/10.1016\/j.autrev.2020.102590 (2020).","journal-title":"Autoimmun. Rev."},{"key":"72864_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40959-021-00106-x","volume":"7","author":"JC Lal","year":"2021","unstructured":"Lal, J. C., Brown, S. A., Collier, P. & Cheng, F. A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors. Cardiooncology. 7, 19. https:\/\/doi.org\/10.1186\/s40959-021-00106-x (2021).","journal-title":"Cardiooncology"},{"key":"72864_CR47","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40959-021-00112-z","volume":"7","author":"S Kazama","year":"2021","unstructured":"Kazama, S. et al. Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review. Cardiooncology. 7, 26. https:\/\/doi.org\/10.1186\/s40959-021-00112-z (2021).","journal-title":"Cardiooncology"},{"key":"72864_CR48","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L. L. & Hansen, A. R. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann. Oncol.28, 2377\u20132385. https:\/\/doi.org\/10.1093\/annonc\/mdx286 (2017).","journal-title":"Ann. Oncol."},{"key":"72864_CR49","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nat. Rev. Clin. Oncol.16, 563\u2013580. https:\/\/doi.org\/10.1038\/s41571-019-0218-0 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"72864_CR50","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMra1613984","volume":"376","author":"MH Rosner","year":"2017","unstructured":"Rosner, M. H. & Perazella, M. A. Acute kidney Injury in patients with Cancer. N Engl. J. Med.376, 1770\u20131781. https:\/\/doi.org\/10.1056\/NEJMra1613984 (2017).","journal-title":"N Engl. J. Med."},{"key":"72864_CR51","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson, J. A. et al. Management of immunotherapy-related toxicities, Version 1.2022, NCCN Clinical Practice guidelines in Oncology. J. Natl. Compr. Canc Netw.20, 387\u2013405. https:\/\/doi.org\/10.6004\/jnccn.2022.0020 (2022).","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"72864_CR52","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1158\/0008-5472.CAN-14-3098","volume":"75","author":"J Peng","year":"2015","unstructured":"Peng, J. et al. Chemotherapy induces programmed cell death-ligand 1 overexpression via the Nuclear factor-kappab to Foster an immunosuppressive Tumor Microenvironment in Ovarian Cancer. Cancer Res.75, 5034\u20135045. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3098 (2015).","journal-title":"Cancer Res."},{"key":"72864_CR53","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","volume":"19","author":"AR Lyon","year":"2018","unstructured":"Lyon, A. R., Yousaf, N., Battisti, N. M. L., Moslehi, J. & Larkin, J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol.19, e447\u2013e458. https:\/\/doi.org\/10.1016\/S1470-2045(18)30457-1 (2018).","journal-title":"Lancet Oncol."},{"key":"72864_CR54","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/ejhf.2289","volume":"23","author":"N Rubio-Infante","year":"2021","unstructured":"Rubio-Infante, N. et al. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur. J. Heart Fail.23, 1739\u20131747. https:\/\/doi.org\/10.1002\/ejhf.2289 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"72864_CR55","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","volume":"65","author":"F Imhann","year":"2016","unstructured":"Imhann, F. et al. Proton pump inhibitors affect the gut microbiome. Gut. 65, 740\u2013748. https:\/\/doi.org\/10.1136\/gutjnl-2015-310376 (2016).","journal-title":"Gut"},{"key":"72864_CR56","doi-asserted-by":"publisher","unstructured":"Amoroso, C. et al. The role of gut microbiota biomodulators on mucosal immunity and intestinal inflammation. Cells. 9. https:\/\/doi.org\/10.3390\/cells9051234 (2020).","DOI":"10.3390\/cells9051234"},{"key":"72864_CR57","doi-asserted-by":"publisher","unstructured":"Ma, C. et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 360https:\/\/doi.org\/10.1126\/science.aan5931 (2018).","DOI":"10.1126\/science.aan5931"},{"key":"72864_CR58","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41586-019-0878-z","volume":"565","author":"T Tanoue","year":"2019","unstructured":"Tanoue, T. et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature. 565, 600\u2013605. https:\/\/doi.org\/10.1038\/s41586-019-0878-z (2019).","journal-title":"Nature"},{"key":"72864_CR59","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1634\/theoncologist.2017-0384","volume":"23","author":"Y Toi","year":"2018","unstructured":"Toi, Y. et al. Association of Immune-related adverse events with Clinical Benefit in patients with Advanced Non-small-cell Lung Cancer treated with Nivolumab. Oncologist. 23, 1358\u20131365. https:\/\/doi.org\/10.1634\/theoncologist.2017-0384 (2018).","journal-title":"Oncologist"},{"key":"72864_CR60","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani, K. et al. Association of Immune-related adverse events with Nivolumab Efficacy in Non-small-cell Lung Cancer. JAMA Oncol.4, 374\u2013378. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2925 (2018).","journal-title":"JAMA Oncol."},{"key":"72864_CR61","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/art.41604","volume":"73","author":"J Aldrich","year":"2021","unstructured":"Aldrich, J. et al. Inflammatory myositis in Cancer patients receiving Immune Checkpoint inhibitors. Arthritis Rheumatol.73, 866\u2013874. https:\/\/doi.org\/10.1002\/art.41604 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"72864_CR62","doi-asserted-by":"publisher","unstructured":"Fazel, M., Jedlowski, P. M. & Severe Myositis Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma. Case Reports Immunol 2539493. https:\/\/doi.org\/10.1155\/2019\/2539493 (2019).","DOI":"10.1155\/2019\/2539493"},{"key":"72864_CR63","doi-asserted-by":"publisher","first-page":"e18040","DOI":"10.7759\/cureus.18040","volume":"13","author":"SJ Bawek","year":"2021","unstructured":"Bawek, S. J., Ton, R., McGovern-Poore, M., Khoncarly, B. & Narvel, R. Nivolumab-Induced Myasthenia Gravis Concomitant with myocarditis, myositis, and Hepatitis. Cureus. 13, e18040. https:\/\/doi.org\/10.7759\/cureus.18040 (2021).","journal-title":"Cureus"},{"key":"72864_CR64","doi-asserted-by":"publisher","unstructured":"Jeyakumar, N. et al. The terrible Triad of Checkpoint Inhibition: a Case Report of Myasthenia Gravis, Myocarditis, and Myositis Induced by Cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma. Case Rep. Immunol. 2020 (5126717). https:\/\/doi.org\/10.1155\/2020\/5126717 (2020).","DOI":"10.1155\/2020\/5126717"},{"key":"72864_CR65","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fphar.2017.00730","volume":"8","author":"PF Wang","year":"2017","unstructured":"Wang, P. F. et al. Immune-related adverse events Associated with Anti-PD-1\/PD-L1 treatment for malignancies: A Meta-analysis. Front. Pharmacol.8, 730. https:\/\/doi.org\/10.3389\/fphar.2017.00730 (2017).","journal-title":"Front. Pharmacol."},{"key":"72864_CR66","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","volume":"19","author":"G Giaccone","year":"2018","unstructured":"Giaccone, G. et al. Pembrolizumab in patients with thymic carcinoma: A single-arm, single-centre, phase 2 study. Lancet Oncol.19, 347\u2013355. https:\/\/doi.org\/10.1016\/S1470-2045(18)30062-7 (2018).","journal-title":"Lancet Oncol."},{"key":"72864_CR67","doi-asserted-by":"publisher","unstructured":"Tateo, V. et al. Immunobiology of thymic epithelial tumors: Implications for immunotherapy with Immune Checkpoint inhibitors. Int. J. Mol. Sci.21https:\/\/doi.org\/10.3390\/ijms21239056 (2020).","DOI":"10.3390\/ijms21239056"},{"key":"72864_CR68","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow, D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol.18, 345\u2013362. https:\/\/doi.org\/10.1038\/s41571-021-00473-5 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"72864_CR69","doi-asserted-by":"publisher","first-page":"102134","DOI":"10.1016\/j.ctrv.2020.102134","volume":"92","author":"S Hussaini","year":"2021","unstructured":"Hussaini, S. et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis. Cancer Treat. Rev.92, 102134. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102134 (2021).","journal-title":"Cancer Treat. Rev."},{"key":"72864_CR70","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41589-022-01017-3","volume":"18","author":"SA Lim","year":"2022","unstructured":"Lim, S. A., Su, W., Chapman, N. M. & Chi, H. Lipid metabolism in T cell signaling and function. Nat. Chem. Biol.18, 470\u2013481. https:\/\/doi.org\/10.1038\/s41589-022-01017-3 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"72864_CR71","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41586-020-2682-1","volume":"585","author":"Y Bian","year":"2020","unstructured":"Bian, Y. et al. Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature. 585, 277\u2013282. https:\/\/doi.org\/10.1038\/s41586-020-2682-1 (2020).","journal-title":"Nature"},{"key":"72864_CR72","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang, C. H. et al. Metabolic competition in the Tumor Microenvironment is a driver of Cancer Progression. Cell. 162, 1229\u20131241. https:\/\/doi.org\/10.1016\/j.cell.2015.08.016 (2015).","journal-title":"Cell"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72864-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72864-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72864-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T14:20:25Z","timestamp":1727446825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72864-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["72864"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-72864-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"26 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22199"}}